CAR-T cell therapy for aggressive B-cell lymphomas
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a type of B-cell non-Hodgkin lymphoma, such as DLBCL, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed lymphoma, mantle cell lymphoma (MCL), or Richter's transformation (RT).
- Your lymphoma must be relapsed (come back) or refractory (not responded) after at least 2 prior treatments for DLBCL, or 1 prior treatment for MCL or RT.
- You must have measurable disease on a PET/CT scan (for systemic lymphoma) or MRI (for CNS lymphoma).
- You must have a recent tumor biopsy sample available or be able to provide one.
- You must have adequate organ function, including kidney, heart, liver, and blood counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
This trial tests a new CAR-T cell therapy for people with high-risk mantle cell lymphoma that hasn't gotten worse after initial treatment. It aims to see if this targeted immunotherapy can improve outcomes for patients with aggressive disease features.
This trial tests a combination of two treatments: a CAR-T cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab) for people with certain types of B-cell lymphoma that have come back or stopped responding to other treatments. The goal is to see if this combination can help control the cancer.
This trial tests a personalized cancer treatment called CAR-T therapy. It uses your own immune cells, which are modified in a lab to fight your specific type of blood cancer, and then given back to you. The goal is to see if this treatment is safe and feasible when produced locally.
This trial tests a new CAR T-cell therapy called MB-CART2019.1 for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded after at least two prior treatments. The therapy uses your own immune cells to fight the cancer.
This trial tests a CAR T-cell therapy (MB-CART2019.1) against standard treatment in people with certain types of aggressive B-cell lymphoma that has come back or didn’t respond to the first treatment. It aims to improve how well the lymphoma responds and to check for side effects and safety.
Hear when a new Transformed Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.